114 research outputs found
Validation of the endothelial markers Cd31 and Cd34 in Immunohistochemistry of the long saphenous vein for coronary artery bypass surgery
Randomized Study Comparing the Effect of Carbon Dioxide Insufflation on Veins Using 2 Types of Endoscopic and Open Vein Harvesting
Study comparing vein integrity and clinical outcomes in open vein harvesting and 2 types of endoscopic vein harvesting for coronary artery bypass grafting:The VICO randomized clinical trial (vein integrity and clinical outcomes)
Amyotrophic lateral sclerosis–specific quality of life–short form (ALSSQOL‐SF): A brief, reliable, and valid version of the ALSSQOL‐R
Introduction: The Amyotrophic Lateral Sclerosis (ALS)‐Specific Quality of Life instrument and its revised version (ALSSQOL and ALSSQOL‐R) have strong psychometric properties, and have demonstrated research and clinical utility. In this study we aimed to develop a short form (ALSSQOL‐SF) suitable for limited clinic time and patient stamina. Methods: The ALSSQOL‐SF was created using Item Response Theory and confirmatory factor analysis on 389 patients. A cross‐validation sample of 162 patients assessed convergent, divergent, and construct validity of the ALSSQOL‐SF compared with psychosocial and physical functioning measures. Results: The ALSSQOL‐SF consisted of 20 items. Compared with the ALSSQOL‐R, optimal precision was retained, and completion time was reduced from 15–25 minutes to 2–4 minutes. Psychometric properties for the ALSSQOL‐SF and its subscales were strong. Discussion: The ALSSQOL‐SF is a disease‐specific global QOL instrument that has a short administration time suitable for clinical use, and can provide clinically useful, valid information about persons with ALS. Muscle Nerve 58: 646–654, 2018Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/146574/1/mus26203_am.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/146574/2/mus26203.pd
Hydrothermal Chimney Distribution on the Endeavour Segment, Juan de Fuca Ridge
The Endeavour Segment of the Juan de Fuca Ridge is well known for its abundance of hydrothermal vents and chimneys. One‐meter scale multibeam mapping data collected by an autonomous undersea vehicle revealed 572 chimneys along the central 14 km of the segment, although only 47 are named and known to be active. Hydrothermal deposits are restricted to the axial graben and the near‐rims of the graben above a seismically mapped axial magma lens. The sparse eruptive activity on the segment during the last 4,300 years has not buried inactive chimneys, as occurs at more magmatically robust mid‐ocean ridges
Hydrothermal Chimney Distribution on the Endeavour Segment, Juan de Fuca Ridge
The Endeavour Segment of the Juan de Fuca Ridge is well known for its abundance of hydrothermal vents and chimneys. One-meter scale multibeam mapping data collected by an autonomous undersea vehicle revealed 572 chimneys along the central 14 km of the segment, although only 47 are named and known to be active. Hydrothermal deposits are restricted to the axial graben and the near-rims of the graben above a seismically mapped axial magma lens. The sparse eruptive activity on the segment during the last 4,300 years has not buried inactive chimneys, as occurs at more magmatically robust mid-ocean ridges
Recommended from our members
Design and Initial Results of a Multi-Phase Randomized Trial of Ceftriaxone in Amyotrophic Lateral Sclerosis
Objectives: Ceftriaxone increases expression of the astrocytic glutamate transporter, EAAT2, which might protect from glutamate-mediated excitotoxicity. A trial using a novel three stage nonstop design, incorporating Phases I-III, tested ceftriaxone in ALS. Stage 1 determined the cerebrospinal fluid pharmacokinetics of ceftriaxone in subjects with ALS. Stage 2 evaluated safety and tolerability for 20-weeks. Analysis of the pharmacokinetics, tolerability, and safety was used to determine the ceftriaxone dosage for Stage 3 efficacy testing. Methods: In Stage 1, 66 subjects at ten clinical sites were enrolled and randomized equally into three study groups receiving intravenous placebo, ceftriaxone 2 grams daily or ceftriaxone 4 grams daily divided BID. Participants provided serum and cerebrospinal fluid for pharmacokinetic analysis on study day 7. Participants continued their assigned treatment in Stage 2. The Data and Safety Monitoring Board (DSMB) reviewed the data after the last participants completed 20 weeks on study drug. Results: Stage 1 analysis revealed linear pharmacokinetics, and CSF trough levels for both dosage levels exceeding the pre-specified target trough level of 1 µM (0.55 µg/mL). Tolerability (Stages 1 and 2) results showed that ceftriaxone at dosages up to 4 grams/day was well tolerated at 20 weeks. Biliary adverse events were more common with ceftriaxone but not dose-dependent and improved with ursodeoxycholic (ursodiol) therapy. Conclusions: The goals of Stages 1 and 2 of the ceftriaxone trial were successfully achieved. Based on the pre-specified decision rules, the DSMB recommended the use of ceftriaxone 4 g/d (divided BID) for Stage 3, which recently closed. Trial Registration ClinicalTrials.gov NCT00349622
A comprehensive review on learning curve associated problems in endoscopic vein harvesting and the requirement for a standardised training programme
Therapeutic Management of Primary Immunodeficiency in Older Patients
Primary immunodeficiency disease (PID) has traditionally been viewed as a group of illnesses seen in the paediatric age group. New advances in diagnosis and treatment have led to an increase in the number of elderly PID patients. However, there is lack of research evidence on which to base clinical management in this group of patients. Management decisions often have to be based therefore on extrapolations from other patient cohorts or from younger patients. Data from the European Society for Immunodeficiencies demonstrates that the vast majority of elderly patients suffer from predominantly antibody deficiency syndromes. We review the management of PID disease in the elderly, with a focus on antibody deficiency disease
Global change at the Paleocene-Eocene boundary: climatic and evolutionary consequences of tectonic events
Events of the Paleocene-Eocene boundary provide the clearest example to date of how a tectonic event may have global climatic consequences. Recent advances permit well-constrained stratigraphic determination of several events that occurred at that boundary, in chron C24R: a many-fold increase in sea-floor hydrothermal activity, a global warming, a reduction in the intensity of atmospheric circulation, a conversion to salinity-driven deep ocean circulation, a marked lightening of oceanic [delta]13C values, extinction and evolution of both benthic foraminifera and land mammals, and important place-boundary reorganizations including the outpouring of the east Greenland volcanics and the initiation of the oceanic rift between Norway and Greenland.We hypothesize that enhanced sea-floor hydrothermal activity occasioned by global tectonism resulted in a flooding of the atmosphere with CO2, causing a reduced pole-to-equator temperature gradient and increased evaporation at low latitudes. Increased formation of warm, salty, probably low-nutrient waters coupled with the warm temperatures at high latitudes occasioned a salinity-driven, rather than temperature-driven, deep-water circulation. This newly-evolved ocean circulation pattern changed the apportionment of global heat transport from the atmosphere to the ocean, with concomitant changes in the circulation intensity of both. Reduced intensity of atmospheric circulation resulted in lower oceanic biological productivity and enhanced seasonality of climate on the continents. A major extinction event among benthic foraminifera was probably a response to the new low-nutrient and chemically changed bottom waters, and endemism following rapid evolution and dispersal of mammalian orders may have been in response to the new continental climate regime.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/28490/1/0000285.pd
- …